amino acid substitution is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
=== Receptor binding === As shown in Table 1, adenylyl cyclase and cAMP assays were used in various functional studies to determine the amount of cAMP inhibition by two CRH1 receptor antagonists: antalarmin and CP-154,526.
visibility and traceability by barcodes for each vaccine vial sharing of supplier audits sharing of chain of custody for a vaccine vial from manufacturer to the individual being vaccinated use of vaccine temperature monitoring tools temperature stability testing and assurance new packaging and delivery technologies stockpiling coordination of supplies within each country (personal protective equipment, diluent, syringes, needles, rubber stoppers, refrigeration fuel or power sources, waste-handling, among others) communications technology environmental impacts in each country A logistics shortage in any one step may derail the whole supply chain, according to one vaccine developer. If the vaccine supply chain fails, the economic and human costs of the pandemic may be extended for years.
) which are the radial, tangential and longitudinal dimensions respectively, in inches, with the longitudinal dimension divided by ten because water diffuses about 10 times more rapidly in the longitudinal direction (along the grain) than in the lateral dimensions. The solution to the above equation is:
The act was revised in 1801 and 1805, and in 1823–24 an elaborate inquiry was followed by an act making quarantine only at the discretion of the Privy Council, which recognised yellow fever or other highly infectious diseases as calling for quarantine, along with plague. The threat of cholera in 1831 was the last occasion in England when quarantine restrictions were used. Cholera affected every country in Europe despite all efforts to keep it out. When cholera returned to England in 1849, 1853, and 1865–66, no attempt was made to seal the ports. In 1847 the privy council ordered all arrivals with a clean bill of health from the Black Sea and the Levant to be admitted, provided there had been no case of plague during the voyage and afterwards, the practice of quarantine was discontinued. In modern maritime law, biosecurity measures for arriving vessels centre on 'pratique', a licence issued by border control officials permitting a ship to enter port, on the assurance of the captain that the vessel is free from contagious disease. The clearance granted is commonly referred to as 'free pratique'. A ship can signal a request for 'pratique' by flying a solid yellow square-shaped flag. This yellow flag is the Q flag in the set of international maritime signal flags. In the event that 'free pratique' is not granted, a vessel will be held in quarantine according to biosecurity rules prevailing at the port of entry until a border control officer inspects the vessel. During the COVID-19 pandemic, a controversy arose as to who granted pratique to the Ruby Princess.
Sources: en.wikipedia.org
John Ronald Reuel Tolkien (; 3 January 1892 – 2 September 1973) was an English writer and academic philologist. He was the author of the high fantasy works The Hobbit (1937) and The Lord of the Rings (1954–1955). From 1925 to 1945 Tolkien was the Rawlinson and Bosworth Professor of Anglo-Saxon and a Fellow of Pembroke College, both at the University of Oxford. He then moved within the same university to become the Merton Professor of English Language and Literature and Fellow of Merton College, and held these positions from 1945 until his retirement in 1959. Tolkien was a devout Catholic and a close friend of C. S. Lewis, a co-member of the Inklings, an informal literary discussion group. He was appointed a Commander of the Order of the British Empire by Elizabeth II on 28 March 1972. After Tolkien's death, his son Christopher published a series of works based on his father's extensive notes and unpublished manuscripts, including The Silmarillion. These, together with The Hobbit and The Lord of the Rings, form a connected body of tales, poems, fictional histories, invented languages, and literary essays about a fantasy world called Arda and, within it, Middle-earth. Between 1951 and 1955 Tolkien applied the term legendarium to the larger part of these writings. While many other authors had published works of fantasy before Tolkien, the tremendous success of The Hobbit and The Lord of the Rings ignited a profound interest in the fantasy genre and ultimately precipitated an avalanche of new fantasy books and authors.
=== Panama === In Panama, there are five public universities, including the University of Panama and the Technological University of Panama. Public universities are state-funded with no cost or minimal tuition, around US$1,500 over four years. Public universities operate autonomously, without intervention from the state. Public universities are prestigious due to their free or low-cost nature, which removes financial incentives to pass and retain students.
== Nomenclature == The name γ-glutamyltransferase is preferred by the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology. The Expert Panel on Enzymes of the International Federation of Clinical Chemistry also used this name. The older name is gamma-glutamyl transpeptidase (GGTP).
== External links == Processing Radioactive Materials - large set of images by the IAEA showing automated package labelling and tracking for shipment of hazardous radioactive pharmaceuticals. FDA Compliance Policy Guides - CPG Sec. 450.500 Tamper-Resistant Packaging Requirements for Certain Over-the-Counter Human Drug Products
== The industry == Within the chemical universe, the fine chemical industry is positioned between the commodity, their suppliers, and specialty chemical industries, their customers. Depending on the services offered, there are two types of fine chemical companies. Fine chemical companies are active in industrial scale production, both of standard and exclusive products. Fine chemical companies tend to fall into one of three categories: producers are referred to as Custom Manufacturing Organizations (CMOs); Contract Research Organizations (CROs)' main assets are their research laboratories; and CRAMS (Contract Research and Manufacturing Organizations are hybrids between the two.
Sources: en.wikipedia.org
The World Health Organization determined that there was little evidence to judge the abuse potential of tapentadol when it was introduced. Although early pre-clinical animal trials suggested that tapentadol had a reduced abuse liability compared to other opioid analgesics, the US Drug Enforcement Agency placed tapentadol into Schedule II, the same category as stronger opioids more commonly used recreationally, such as morphine, oxycodone, and fentanyl. Since these initial trials, however, evidence has shown that tapentadol is commonly abused, misused and diverted, that it is addictive, and that it poses a high risk of physical and/or mental dependence. Given that tapentadol is a highly selective full agonist of the μ-opioid receptor, and given that is not a pro-drug, with no ceiling effect, studies have found that it is significantly more abusable than tramadol, and similar to hydrocodone and other full agonists of the μ-opioid receptor (such as oxycodone and hydromorphone) in terms of addiction and dependence liability. Tapentadol is water soluble, which creates the potential for further abuse of the drug. There have been reports of users crushing, chewing, inhaling or injecting immediate-release tapentadol tablets, which can lead to respiratory depression, and death.
== Research == In 2015, Merck reported results in thirteen cancer types; much attention was given to early results in head and neck cancer. As of May 2016, pembrolizumab was in phase IB clinical trials for triple-negative breast cancer (TNBC), gastric cancer, urothelial cancer, and head and neck cancer (all under the "Keynote-012" trial) and in phase II trial for TNBC (the "Keynote-086" trial). At ASCO, in June 2016, Merck reported that the clinical development program was directed to around 30 cancers and that it was running over 270 clinical trials (around 100 in combination with other treatments) and had four registration-enabling studies in process. Results of a phase III clinical trial in triple-negative breast cancer were reported in October 2019. Results of a phase II clinical trial in Merkel-cell carcinoma were reported in June 2016. Results of a clinical trial in people with untreatable metastases arising from various solid tumors were reported in 2017. A clinical phase III trial in combination with epacadostat, an Indoleamine 2,3-dioxygenase (IDO1) inhibitor to treat melanoma was completed in 2019. In 2021, researchers reported the results of a five-year follow-up study. In January 2022, a combination clinical trial of pembrolizumab and NL-201, a de novo protein undergoing a phase I clinical trial in people with advanced, relapsed or refractory solid tumors. In March 2023, Merck reported the results of NRG-GY018, a phase III clinical trial in people with stage three to four or recurrent endometrial carcinoma.
Ryan takes control of Jack's actions by asking, "Would you kindly?"; a phrase that has preceded many of Atlas's commands as a hypnotic trigger, forcing him to follow any orders without question. Jack also realizes he was responsible for the plane crash, having read a letter onboard containing the same trigger phrase. Ryan chooses to die by his own will and compels Jack to beat him to death with a golf club. Atlas reveals himself to be Fontaine, having faked his death and used "Atlas" as an alias to hide his identity while providing a heroic figure for the poor to rally behind. With Ryan dead, Fontaine takes control of the city and leaves Jack to be killed by hostile security drones. Jack is saved by Dr. Tenenbaum, who helps remove Fontaine's mental conditioning, including one that would have stopped Jack's heart. Jack pursues Fontaine to his lair, where Fontaine transforms himself into a hulking humanoid creature by injecting himself with a large supply of ADAM. The Little Sisters aid Jack in draining the ADAM from Fontaine's body and eventually kill him. The ending depends on how the player interacts with the Little Sisters:
== Technology == Aroa Biosurgery develops medical devices using its proprietary ovine forestomach matrix (OFM) technology. OFM is a layer of decellularized extracellular matrix (ECM) biomaterial isolated from the propria submucosa of the rumen of sheep. OFM is used in tissue engineering and as a tissue scaffold for wound healing and surgical applications.
The restaurants serve Korean food, including kimchi dishes, Pyongyang cold noodles, barbecued cuttlefish and dog meat soup. Patrons may also buy North Korean products such as ginseng wine and an unlabelled aphrodisiac claimed to be made from bears. The prices are relatively high and in US dollars. The staff consists of young Korean women in traditional Chosŏn-ot dress, who also perform karaoke as well as song and dance routines in the style of the North Korean Mass Games for the customers. Staff from North Korea typically work on three-year contracts, and are often highly trained graduates of arts colleges. Photography is generally not permitted inside.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.